NKGen Biotech Will Present New Biomarker Data On SNK01 (Autologous Non-genetically Modified Nk Cell Therapy) In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August 1
NKGen Biotech Will Present New Biomarker Data On SNK01 (Autologous Non-genetically Modified Nk Cell Therapy) In Alzheimer's Disease During A Poster Presentation At The Upcoming Alzheimer's Association International Conference From July 28 – August 1
NKGen生物技術公司將在即將到來的阿爾茨海默協會國際會議上通過海報展示關於SNK01（自體非基因修飾NK細胞療法）在阿爾茨海默病中的新生物標誌數據，時間爲7月28日至8月1日。
NKGen will present data on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant given that α-synuclein has been shown to correlate with worse cognitive function in Alzheimer's disease.
NKGen將呈現SNK01降低阿爾茨海默病α-突觸核蛋白能力的數據，這一點非常重要，因爲α-突觸核蛋白已被證明與阿爾茨海默病的認知功能下降相關。
資訊熱榜
更新時間